| Literature DB >> 34313219 |
Jie Lisa Ji1,2, Markus Helmer1, Clara Fonteneau1, Joshua B Burt3, Zailyn Tamayo1, Jure Demšar4,5, Brendan D Adkinson1,2, Aleksandar Savić6, Katrin H Preller7, Flora Moujaes7, Franz X Vollenweider7, William J Martin8, Grega Repovš6, Youngsun T Cho1,9, Christopher Pittenger1,9, John D Murray1,2,10, Alan Anticevic1,2,11.
Abstract
Difficulties in advancing effective patient-specific therapies for psychiatric disorders highlight a need to develop a stable neurobiologically grounded mapping between neural and symptom variation. This gap is particularly acute for psychosis-spectrum disorders (PSD). Here, in a sample of 436 PSD patients spanning several diagnoses, we derived and replicated a dimensionality-reduced symptom space across hallmark psychopathology symptoms and cognitive deficits. In turn, these symptom axes mapped onto distinct, reproducible brain maps. Critically, we found that multivariate brain-behavior mapping techniques (e.g. canonical correlation analysis) do not produce stable results with current sample sizes. However, we show that a univariate brain-behavioral space (BBS) can resolve stable individualized prediction. Finally, we show a proof-of-principle framework for relating personalized BBS metrics with molecular targets via serotonin and glutamate receptor manipulations and neural gene expression maps derived from the Allen Human Brain Atlas. Collectively, these results highlight a stable and data-driven BBS mapping across PSD, which offers an actionable path that can be iteratively optimized for personalized clinical biomarker endpoints.Entities:
Keywords: fMRI; human; neuroscience; precision neuroimaging; psychiatric disorders; psychosis
Mesh:
Year: 2021 PMID: 34313219 PMCID: PMC8315806 DOI: 10.7554/eLife.66968
Source DB: PubMed Journal: Elife ISSN: 2050-084X Impact factor: 8.713